Cancers Treated:
Research Interests:
- Immunotherapy outcomes and immune-related adverse events
- Real-world data analysis and translational oncology research aimed at integrating molecular and clinical data to improve therapeutic strategies and patient outcomes
- Cancer epidemiology
Biography
I am a board certified hematologist and medical oncologist. I provide evidenced-based cancer care while working in partnership with patients and their families, with an emphasis on clear communication, shared decision making and compassionate support during a life-changing diagnosis and treatment journey.
My academic interests include translational oncology research with a particular emphasis on sarcoma.
Positions
Roswell Park Comprehensive Cancer Center
- Assistant Professor of Oncology
- Department of Medicine
Background
Education and Training
- 2016 - MBBS - University of Jammu, Jammu, India
Residency
- 2021-2022 - Chief Resident Internal Medicine - Rutgers Health, New Jersey Medical School / Cooperman Barnabas Medical Center, Livingston, NJ
- 2018-2021 - Internal Medicine Residency - Rutgers Health, Saint Barnabas Medical Center, Livingston, NJ
Fellowship
- 2022-2025 - Hematology and Medical Oncology Fellowship - Allegheny Health Network / Allegheny Health Consortium, Pittsburgh, PA
Board Certification
- American Board of Internal Medicine – Internal Medicine
- American Board of Internal Medicine – Hematology
- American Board of Internal Medicine – Medical Oncology
Professional Memberships
- American Society of Clinical Oncology
- American Society of Hematology
- American College of Physicians
- American Medical Association
Honors & Awards
- 2021–2022 - Barbara Sloan Patient Comfort and Humanism Award
- 2019–2020 - Albert N. Siegel, MD Memorial Award – Excellence in Gastroenterology
- 2018–2019 - Carlos Hormilla, MD Memorial Award – Outstanding Intern of the Year
Publications
1. Laharwal M, et al. Hepatic portal venous gas associated with colon adenocarcinoma. QJM. 2020.
2. Naqash AR, Moey MYY, Tan XWC, Laharwal M, et al. Major adverse cardiac events with immune checkpoint inhibitors. Journal of Clinical Oncology. 2022.
3. Ruiz EF, Ahsan M, Laharwal M. The hardest pill to swallow: A freak of nature.
4. Hsiehchen D, Naqash AR, Espinoza M, Laharwal M, et al. Immune-related adverse event timing and treatment outcomes. OncoImmunology. 2022.
5. Sweeney R, Laharwal M, Shah D. Secondary erythrocytosis as a presenting feature of CNS hemangioblastoma. Clinical Images and Case Reports.
2. Naqash AR, Moey MYY, Tan XWC, Laharwal M, et al. Major adverse cardiac events with immune checkpoint inhibitors. Journal of Clinical Oncology. 2022.
3. Ruiz EF, Ahsan M, Laharwal M. The hardest pill to swallow: A freak of nature.
4. Hsiehchen D, Naqash AR, Espinoza M, Laharwal M, et al. Immune-related adverse event timing and treatment outcomes. OncoImmunology. 2022.
5. Sweeney R, Laharwal M, Shah D. Secondary erythrocytosis as a presenting feature of CNS hemangioblastoma. Clinical Images and Case Reports.